| Third-generation long-acting β(2)-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β(2)-adrenoceptor agonists. | |
| | |
MedLine Citation:
|
PMID: 21942251 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Inhaled long-acting β(2)-adrenoceptor agonists (LABAs) are highly effective bronchodilators in the treatment of asthma and chronic obstructive pulmonary disease. There is significant interest in the development of third-generation compounds that improve upon the marketed twice-daily LABAs salmeterol and formoterol. A principal advantage sought from the next generation is duration of action that supports once-daily dosing, although improved efficacy, faster onset, and increased therapeutic index are also frequently cited as objectives. Recent publications detailing medicinal chemistry programs directed at the discovery of third-generation LABAs illustrate a wide variety of strategies that have been successfully employed towards these goals. Some recent scientific advances in the understanding of inhaled bronchodilators are discussed and the reported medicinal chemistry strategies are reviewed in the context of these advances. |
| | |
Authors:
|
John R Jacobsen |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Future medicinal chemistry Volume: 3 ISSN: 1756-8927 ISO Abbreviation: Future Med Chem Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101511162 Medline TA: Future Med Chem Country: England |
Other Details:
|
Languages: eng Pagination: 1607-22 Citation Subset: IM |
Affiliation:
|
Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080, USA. jjacobsen@theravance.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dual-pharmacology muscarinic antagonist and ?(2) agonist molecules for the treatment of chronic obst...
Next Document: Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease.